Corvus Pharmaceuticals
CRVS
48 hedge funds and large institutions have $18.1M invested in Corvus Pharmaceuticals in 2022 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 10 increasing their positions, 12 reducing their positions, and 5 closing their positions.
33% more call options, than puts
Call options by funds: $40K | Put options by funds: $30K
20% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 5
2% more funds holding
Funds holding: 47 → 48 (+1)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
7.54% less ownership
Funds ownership: 55.01% → 47.47% (-7.5%)
17% less repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 12
29% less capital invested
Capital invested by funds: $25.4M → $18.1M (-$7.27M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CA
CHI Advisors
New York
|
+$162K |
| 2 |
Two Sigma Advisers
New York
|
+$102K |
| 3 |
Two Sigma Investments
New York
|
+$65.5K |
| 4 |
TI
Telemetry Investments
New York
|
+$59.1K |
| 5 |
B
Bailard
Foster City,
California
|
+$38.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
Tang Capital Management
San Diego,
California
|
-$3.27M |
| 2 |
Millennium Management
New York
|
-$403K |
| 3 |
Dimensional Fund Advisors
Austin,
Texas
|
-$187K |
| 4 |
Goldman Sachs
New York
|
-$21.6K |
| 5 |
Group One Trading
Chicago,
Illinois
|
-$20.7K |
CRVS Hedge Fund Activity: Q3 2022 in Review
48 of the 5,828 institutional investors tracked by Wall St. Rank reported a position in Corvus Pharmaceuticals (CRVS) for Q3 2022, worth a combined $18.1M — down 29% from $25.4M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new CRVS positions and 5 closed out — a net gain of 1 holder — while 10 added to existing stakes and 12 trimmed.
The largest buyer was CHI Advisors, adding an estimated $162K. The largest seller was Tang Capital Management, exiting entirely with an estimated $3.27M sold.
- 48 institutional investors held Corvus Pharmaceuticals (CRVS) as of Q3 2022, up from 47 in Q2 2022.
- Funds reported $18.1M of Corvus Pharmaceuticals stock for Q3 2022, down 29% quarter-over-quarter.
- 6 funds opened new Corvus Pharmaceuticals positions in Q3 2022 and 5 closed out, a net change of +1 holder.
- The largest Corvus Pharmaceuticals buyer in Q3 2022 was CHI Advisors, an estimated $162K added.
- The largest Corvus Pharmaceuticals seller in Q3 2022 was Tang Capital Management, an estimated $3.27M sold.
Based on aggregated 13F filings for Q3 2022.